v3.26.1
Segment Reporting
6 Months Ended
Jun. 30, 2026
Segment Reporting  
Segment Reporting

Note 16. Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer.

“Adjusted EBITDA,” which is defined by the Company as earnings before interest, income taxes, depreciation, amortization and certain items that do not contribute directly to management’s evaluation of its operating results, is the profit measure used by the CODM for each operating segment in measuring the performance of the business and in the annual budget and forecasting process. Asset information by reportable segment is not provided to the CODM.

We have two operating segments that are aggregated under our Life Sciences Services reportable segment, which provides temperature-controlled logistics, biostorage, bioservices and cryopreservation services within the life science industry through direct sales. Revenue from this reportable segment is primarily comprised of Life Sciences Services revenue and includes certain immaterial revenue from the sale of accessories that constitute Life Sciences Products revenue. The Company’s Life Sciences Products reportable segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Revenue from this reportable segment is exclusively Life Sciences Products revenue.

In addition, the CODM manages and evaluates the operating performance of the segments, as described above, on a pre-corporate cost allocation basis. Accordingly, for segment reporting purposes, the Company does not allocate corporate costs, which include certain aspects of the Company’s executive management, legal, compliance, human resources, information technology and finance departments, to its reportable segments.

Information about our segments is as follows (in thousands):

Three Months Ended June 30, 2026

Three Months Ended June 30, 2025

Six Months Ended June 30, 2026

Six Months Ended June 30, 2025

  ​ ​ ​

Life Sciences Services

  ​ ​ ​

Life Sciences Products

  ​ ​ ​

Total

  ​ ​ ​

Life Sciences Services

  ​ ​ ​

Life Sciences Products

  ​ ​ ​

Total

  ​ ​ ​

Life Sciences Services

  ​ ​ ​

Life Sciences Products

  ​ ​ ​

Total

  ​ ​ ​

Life Sciences Services

  ​ ​ ​

Life Sciences Products

  ​ ​ ​

Total

  ​ ​ ​

Revenue from external customers 1

$

28,215

$

20,756

$

48,971

$

25,818

$

19,636

$

45,454

$

55,650

$

41,119

$

96,769

$

49,031

$

37,463

$

86,494

Intersegment revenue

 

466

 

787

 

1,253

 

204

 

357

 

561

 

944

1,281

 

2,225

 

449

 

507

 

956

28,681

21,543

50,224

26,022

19,993

46,015

56,594

42,400

98,994

49,480

37,970

87,450

Reconciliation of revenue

Elimination of intersegment revenue

(1,253)

(561)

(2,225)

(956)

Total consolidated revenue

48,971

45,454

96,769

86,494

Less:

Cost of revenue 1, 2, 3

6,286

9,328

7,180

8,134

13,336

18,397

13,840

15,467

Employee related expenses

15,933

6,062

13,126

5,627

30,795

12,016

26,177

11,062

Engineering and development expense 4, 5

265

408

930

557

467

921

1,913

969

Rent

2,017

167

1,894

186

3,868

345

3,697

373

Other segment items 6

2,529

1,285

2,946

1,478

6,573

2,761

6,391

2,578

Adjusted EBITDA for reportable segments

$

1,651

$

4,293

$

5,944

$

(54)

$

4,011

$

3,957

$

1,555

$

7,960

$

9,515

$

(2,538)

$

7,521

$

4,983

Corporate overhead costs

(5,569)

(4,871)

(9,751)

(8,716)

Depreciation and amortization expense

(6,589)

(6,249)

(12,991)

(12,383)

Acquisition and integration costs

-

(30)

-

(31)

Cost reduction initiatives

(140)

(266)

(140)

(482)

Investment income

3,132

1,466

6,222

3,039

Unrealized gain (loss) on investments

212

(1,082)

(1,893)

(1,275)

Foreign currency loss

(651)

(2,002)

(1,105)

(2,247)

Interest expense, net

(518)

(618)

(950)

(1,201)

Stock-based compensation expense

(2,402)

(2,045)

(4,797)

(5,109)

Change in fair value of contingent consideration

(27)

-

(42)

5,178

Income taxes

(505)

(274)

(613)

(508)

Other unallocated expenses

(1,142)

-

(1,142)

-

Loss from continuing operations

$

(8,255)

$

(12,014)

$

(17,687)

$

(18,752)

(1) Life Sciences Services segment includes immaterial revenue from external customers and cost of revenue associated with Life Sciences Products revenue and Life Sciences Products cost of products revenue, respectively.

(2) Cost of revenue is exclusive of employee related expenses of $8.0 million and $6.9 million, depreciation and amortization of $2.4 million and $2.1 million, stock-based compensation of $0.4 million and $0.5 million, and rent of $0.6 million and $0.7 million for the three months ended June 30, 2026 and 2025, respectively.

(3) Cost of revenue is exclusive of employee related expenses of $15.5 million and $13.8 million, depreciation and amortization of $4.6 million and $4.1 million, stock-based compensation of $0.8 million and $1.1 million, and rent of $1.2 million and $1.5 million for the six months ended June 30, 2026 and 2025, respectively.

(4) Engineering and development expense is exclusive of employee related expenses of $3.5 million and $2.4 million, stock-based compensation of $0.2 million and $0.2 million, and depreciation and amortization of $0.2 million and $0.1 million for the three months ended June 30, 2026 and 2025, respectively.

(5) Engineering and development expense is exclusive of employee related expenses of $6.4 million and $4.7 million, depreciation and amortization of $0.3 million and $0.2 million, and stock-based compensation of $0.4 million and $0.4 million for the six months ended June 30, 2026 and 2025, respectively.

(6) Other segment items primarily includes professional services, facility allocations, dues and subscriptions, audit fees, insurance, legal fees, and travel expense.